Anti-hepatitis b virus treatment with tenofovir amibufenamide has no impact on blood lipids: A real-world, prospective, 48-week follow-up study
2024-10-26
(Press-News.org) Background and Aims
The effect of tenofovir amibufenamide (TMF) on blood lipid profiles in patients with chronic hepatitis B (CHB) remains unclear. This study aimed to explore whether TMF affects blood lipids during 48 weeks in patients with CHB.
Methods
A total of 91 patients with CHB undergoing TMF treatment for 48 weeks were divided into two groups: Lipid Normal (n = 42) and Lipid Abnormal (n = 49), based on baseline blood lipid levels. Lipid indices, virological responses, and biochemical indicators were compared between the two groups. Clinical observations were further verified through in vitro experiments.
Results
After an average follow-up of 373 ± 121 days, lipid indices in all 91 patients had not significantly changed compared with baseline (total cholesterol: 4.67 vs. 4.69 mmol/L, P = 0.2499; triglycerides: 1.08 vs. 1.04 mmol/L, P = 0.4457; high-density lipoprotein cholesterol: 1.25 vs. 1.25 mmol/L, P = 0.3063; low-density lipoprotein cholesterol: 3.03 vs. 3.02 mmol/L, P = 0.5765). Subgroup comparisons showed lipid indices remained stable. Among treatment-naïve patients (n = 82), complete viral suppression rates were 23.2%, 59.8%, 70.7%, and 86.6% at four, 12, 24, and 48 weeks, respectively. Cellular experiments revealed that TMF did not promote lipid metabolism in primary hepatocytes and AML12 cells.
Conclusions
Regardless of baseline blood lipid characteristics, 48 weeks of antiviral treatment with TMF in patients with CHB had no significant lipid-raising effect.
Full text
https://www.xiahepublishing.com/2310-8819/JCTH-2024-00237
The study was recently published in the Journal of Clinical and Translational Hepatology.
The Journal of Clinical and Translational Hepatology (JCTH) is owned by the Second Affiliated Hospital of Chongqing Medical University and published by XIA & HE Publishing Inc. JCTH publishes high quality, peer reviewed studies in the translational and clinical human health sciences of liver diseases. JCTH has established high standards for publication of original research, which are characterized by a study’s novelty, quality, and ethical conduct in the scientific process as well as in the communication of the research findings. Each issue includes articles by leading authorities on topics in hepatology that are germane to the most current challenges in the field. Special features include reports on the latest advances in drug development and technology that are relevant to liver diseases. Regular features of JCTH also include editorials, correspondences and invited commentaries on rapidly progressing areas in hepatology. All articles published by JCTH, both solicited and unsolicited, must pass our rigorous peer review process.
Follow us on X: @xiahepublishing
Follow us on LinkedIn: Xia & He Publishing Inc.
END
ELSE PRESS RELEASES FROM THIS DATE:
2024-10-26
Tokyo, Japan – Researchers from Tokyo Metropolitan University have uncovered new insights into how the proteins GRB2 and SOS1 in cells pass signals from membrane receptors to nuclei. They used nuclear magnetic resonance (NMR) to study how and which specific regions of GRB2 and SOS1 bind to each other, especially how they trigger liquid-liquid phase separation (LLPS). Issues with signal transduction are a major cause of cancers: understanding how it works may lead to radical new treatments.
Biological ...
2024-10-26
San Diego, CA (October 25, 2024) — Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings will be presented at ASN Kidney Week 2024 October 23– 27.
For the study, investigators analyzed ...
2024-10-26
San Diego, CA (October 25, 2024) — Prior efforts to identify novel kidney biomarkers as risk factors for chronic kidney disease (CKD) progression have typically evaluated proteins individually, which limits their prognostic power. The National Institute of Diabetes and Digestive and Kidney Diseases’ (NIDDK’s) CKD Biomarkers Consortium of investigators recently developed and tested novel dimensions of kidney health by combining a set of 17 urine and plasma biomarkers that ...
2024-10-26
San Diego, CA (October 25, 2024) — IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce proteinuria and maintain patients’ kidney function. Investigators evaluated the molecular mechanisms underlying felzartamab’s potential efficacy in IgAN. The findings will be presented at ASN Kidney Week 2024 October 23– 27.
It is hypothesized that CD38+ cells ...
2024-10-26
San Diego, CA (October 25, 2024) — Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients’ age. A recent analysis of clinical trial data reveals that the SGLT2 inhibitor canagliflozin benefited patients across all age categories. The findings will be presented at ASN Kidney Week 2024 October 23 – 27.
The analysis pooled individual participant data from the CANVAS Program and CREDENCE trial and assessed efficacy and safety according to baseline age. ...
2024-10-25
The Arctic is warming at three to four times the global average. However, new research suggests the slowing of a key ocean current could reduce projected Arctic warming by up to 2 degrees Celsius by the end of the century.
For years, scientists have warned that unchecked Arctic warming could lead to devastating consequences, threatening wildlife and ushering in an era of more frequent and extreme weather events. Amid concerns for these types of outcomes, a study led by UC Riverside offers some limited relief.
The study, published in the Proceedings of the National Academy of Sciences, examined ...
2024-10-25
San Diego, CA (October 25, 2024) — A recent analysis reveals that the number of chronic kidney disease (CKD) cases in women around the globe nearly tripled in the past three decades. Also, type 2 diabetes and hypertension were the leading causes of CKD-related deaths in women. The research will be presented at ASN Kidney Week 2024 October 23– 27.
The analysis drew from the Global Burden of Disease study 2021, a comprehensive effort to quantify health loss across the world over time. The study includes information from 204 countries and territories.
From 1990 to 2021, the average annual percentage ...
2024-10-25
Ever had an itchy nose or, worse, an unreachable spot on your back that drives you mad? Now imagine an itch that refuses to go away, no matter how hard or long you scratch. That persistent itch, or pruritus, may actually be one of the skin’s first lines of defense against harmful invaders, according to neuroimmunologist Juan Inclan-Rico of the University of Pennsylvania.
“It’s inconvenient, it’s annoying, but sensations like pain and itch are crucial. They’re ever-present, especially when it comes to skin infections,” says Inclan-Rico, a postdoctoral researcher in the Herbert Lab at ...
2024-10-25
It feels like narcissism is everywhere these days: politics, movies and TV, sports, social media. You might even see signs of it at work, where it can be particularly detrimental. Is it possible to keep a workplace free of destructive, manipulative egotists?
More and more organizations have come to San Francisco State University’s experts in organizational psychology asking for help doing just that. In response, University researchers developed a tool for job interviews to assess narcissistic grandiosity among potential job candidates. San Francisco State Psychology Professors Kevin Eschleman and Chris ...
2024-10-25
You have likely not spent much time thinking about the uterus of the fruit fly, Drosophila melanogaster. But then, neither have most scientists, even though Drosophila is one of the most thoroughly studied lab animals. Now a team of biologists at the University of California, Davis, has taken the first deep look at the Drosophila uterus and found some surprises, which could have implications not just for understanding insect reproduction and potentially, pest control, but also for understanding fertility in humans.
The work is published Oct. 25 in Proceedings of the National Academy of Sciences.
Drosophila have been a favorite subject for ...
LAST 30 PRESS RELEASES:
[Press-News.org] Anti-hepatitis b virus treatment with tenofovir amibufenamide has no impact on blood lipids: A real-world, prospective, 48-week follow-up study
